Royal Bank of Canada’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Royal Bank of Canada’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-27,621	Closed	-$184K	–	7805
2023 Q3	$184K	Buy	27,621 +11,163	+68%	+$92.8K	﹤0.01%	4890
2023 Q2	$150K	Buy	16,458 +4,554	+38%	+$40.2K	﹤0.01%	5002
2023 Q1	$86K	Sell	11,904 -15,063	-56%	-$112K	﹤0.01%	5298
2022 Q4	$196K	Sell	26,967 -220,135	-89%	-$1.63M	﹤0.01%	4907
2022 Q3	$1.91M	Buy	247,102 +514	+0.2%	+$4.36K	﹤0.01%	2891
2022 Q2	$1.68M	Sell	246,588 -302,871	-55%	-$2.32M	﹤0.01%	3046
2022 Q1	$4.38M	Buy	549,459 +545,356	+13,292%	+$3.46M	﹤0.01%	2369
2021 Q4	$23K	Buy	4,103 +1,103	+37%	+$8.28K	﹤0.01%	6747
2021 Q3	$23K	Buy	+3,000	New	+$27.4K	﹤0.01%	6644

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Royal Bank of Canada's PNT Position: Q4 2023 in Review

Royal Bank of Canada sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 27,621 shares — an estimated $184K sold.

Royal Bank of Canada first reported a position in PNT in Q3 2021 and held it in 9 quarters. The position peaked at $4.38M in Q1 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Royal Bank of Canada reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Royal Bank of Canada sold 27,621 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $184K.
Royal Bank of Canada first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Royal Bank of Canada's POINT Biopharma Global Inc. Common Stock position peaked at $4.38M in Q1 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Royal Bank of Canada's 13F filing for Q4 2023, filed 14 Feb 2024.